NCT00415506View on ClinicalTrials.gov

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

ScleritisOrbital Disease

Interventions

DRUG

Rituximab

Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Oregon Health and Science University

OTHER